Waltham startup's future rests on a single molecule

Xconomy reports on Proteon Therapeutics, whose sole potential product is an enzyme aimed at breaking up the fiber formed by blood vessels when they're cut into. It's aimed at long-term kidney-dialysis patients who first undergo surgery aimed at toughening up a vein to withstand the repeated punctures required for dialysis.

Neighborhoods: 

Topics: 

Free tagging: